TY - JOUR
T1 - Delayed Coronary Obstruction After Transcatheter Aortic Valve Replacement
AU - Jabbour, Richard J.
AU - Tanaka, Akihito
AU - Finkelstein, Ariel
AU - Mack, Michael
AU - Tamburino, Corrado
AU - Van Mieghem, Nicolas
AU - de Backer, Ole
AU - Testa, Luca
AU - Gatto, Pamela
AU - Purita, Paola
AU - Rahhab, Zouhair
AU - Veulemans, Verena
AU - Stundl, Anja
AU - Barbanti, Marco
AU - Nerla, Roberto
AU - Sinning, Jan Malte
AU - Dvir, Danny
AU - Tarantini, Giuseppe
AU - Szerlip, Molly
AU - Scholtz, Werner
AU - Scholtz, Smita
AU - Tchetche, Didier
AU - Castriota, Fausto
AU - Butter, Christian
AU - Søndergaard, Lars
AU - Abdel-Wahab, Mohamed
AU - Sievert, Horst
AU - Alfieri, Ottavio
AU - Webb, John
AU - Rodés-Cabau, Josep
AU - Colombo, Antonio
AU - Latib, Azeem
N1 - Funding Information:
Dr. Mack is a coprincipal investigator of the Partner 3 Trial sponsored by Edwards Lifesciences. Dr. Tamburino has served as a consultant for Medtronic and St. Jude Medical. Dr. Van Mieghem has received research grant support from Medtronic, Boston Scientific, Abbott, Essential Medical, Claret, and Edwards Lifesciences. Dr. de Backer has served as a consultant for St. Jude Medical and Abbott Medical. Dr. Barbanti has served as a consultant for Edwards Lifesciences. Dr. Sinning has received research grants and speaker honoraria from Medtronic, Edwards Lifesciences, and Boston Scientific. Dr. Dvir has served as a consultant to Edwards Lifesciences, Medtronic, Abbott, and Gore. Dr. Szerlip has served as a speaker and a proctor for Edwards Lifesciences; and as a speaker for Medtronic. Dr. Castriota has served as a proctor for Boston Scientific, Medtronic, Abbott, and Terumo. Dr. Søndergaard has served as a proctor for, received research contracts from, and served on the advisory boards of Medtronic, St. Jude Medical, and Boston Scientific. Dr. Abdel-Wahab has served as a consultant to Boston Scientific; and has received institutional research grants from Medtronic, St. Jude Medical, and Biotronik. Prof. Sievert has received study honoraria, travel expenses, and consulting fees from 4tech Cardio, Abbott, Ablative Solutions, Ancora Heart, Bavaria Medizin Technologie, Bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Celonova, Cibiem, CGuard, Comed, Contego, CVRx, Edwards, Endologix, Hemoteq, InspireMD, Lifetech, Maquet Getinge Group, Medtronic, Mitralign, Occlutech, pfm Medical, Recor, Renal Guard, Rox Medical, St. Jude Medical, Terumo, Vascular Dynamics, Venus, and Veryan. Dr. Webb has served as a consultant for Edwards Lifesciences and Abbott. Dr. Rodes-Cabau has received research grants from Edwards Lifesciences, Medtronic, and St. Jude Medical. Dr. Latib has served on the advisory board of and as a consultant for Medtronic; has received speaking honoraria from Abbott Vascular; and has received research grants from Medtronic and Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2018
PY - 2018/4/10
Y1 - 2018/4/10
N2 - Background: Delayed coronary obstruction (DCO) is an uncommon and barely reported complication following transcatheter aortic valve replacement (TAVR). Objectives: The aim of this study was to describe the incidence and pathophysiological features of DCO after TAVR, obtained from a large international multicenter registry. Methods: Data were retrospectively collected from an international multicenter registry consisting of 18 centers between November 2005 and December 2016. Results: During the study period, 38 DCO (incidence 0.22%) cases were identified from a total of 17,092 TAVR procedures. DCO occurred more commonly after valve-in-valve procedures (0.89% vs. 0.18%; p < 0.001) and if self-expandable valves were used during the index procedure (0.36% vs. 0.11% balloon expandable; p < 0.01). DCO was most likely to occur ≤24 h after the TAVR procedure (47.4%; n = 18); 6 (15.8%) cases occurred between 24 h and ≤7 days, with the remaining 14 (36.8%) at ≥60 days. The most frequent presentation was cardiac arrest (31.6%; n = 12), followed by ST-segment elevation myocardial infarction (23.7%; n = 9). The left coronary artery was obstructed in most cases (92.1%; n = 35). Percutaneous coronary intervention was attempted in the majority of cases (74.3% left main; 60% right coronary), and stent implantation was successful in 68.8%. The overall in-hospital death rate was 50% (n = 19), and was higher if DCO occurred ≤7 days from the index procedure (62.5% vs. 28.6%; p = 0.09). Conclusions: DCO following TAVR is a rare phenomenon that is associated with a high in-hospital mortality rate. Clinicians should be aware that coronary obstruction can occur after the original TAVR procedure and have a low threshold for performing coronary angiography when clinically suspected.
AB - Background: Delayed coronary obstruction (DCO) is an uncommon and barely reported complication following transcatheter aortic valve replacement (TAVR). Objectives: The aim of this study was to describe the incidence and pathophysiological features of DCO after TAVR, obtained from a large international multicenter registry. Methods: Data were retrospectively collected from an international multicenter registry consisting of 18 centers between November 2005 and December 2016. Results: During the study period, 38 DCO (incidence 0.22%) cases were identified from a total of 17,092 TAVR procedures. DCO occurred more commonly after valve-in-valve procedures (0.89% vs. 0.18%; p < 0.001) and if self-expandable valves were used during the index procedure (0.36% vs. 0.11% balloon expandable; p < 0.01). DCO was most likely to occur ≤24 h after the TAVR procedure (47.4%; n = 18); 6 (15.8%) cases occurred between 24 h and ≤7 days, with the remaining 14 (36.8%) at ≥60 days. The most frequent presentation was cardiac arrest (31.6%; n = 12), followed by ST-segment elevation myocardial infarction (23.7%; n = 9). The left coronary artery was obstructed in most cases (92.1%; n = 35). Percutaneous coronary intervention was attempted in the majority of cases (74.3% left main; 60% right coronary), and stent implantation was successful in 68.8%. The overall in-hospital death rate was 50% (n = 19), and was higher if DCO occurred ≤7 days from the index procedure (62.5% vs. 28.6%; p = 0.09). Conclusions: DCO following TAVR is a rare phenomenon that is associated with a high in-hospital mortality rate. Clinicians should be aware that coronary obstruction can occur after the original TAVR procedure and have a low threshold for performing coronary angiography when clinically suspected.
KW - TAVI
KW - TAVR
KW - coronary obstruction
KW - transcatheter aortic valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85044172355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044172355&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2018.01.066
DO - 10.1016/j.jacc.2018.01.066
M3 - Article
C2 - 29622157
AN - SCOPUS:85044172355
SN - 0735-1097
VL - 71
SP - 1513
EP - 1524
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 14
ER -